The Economic Times daily newspaper is available online now.

    There're lots of challenges due to triple impact in the pharma sector: Sanjay Jain, CFO, FDC

    Synopsis

    In an interview with ET NOW, Sanjay Jain, CFO, FDC talks about the reasons behind company's revenue surge, growth plans and the challenges they are facing. Excerpts:

    ET Now
    In an interview with ET NOW, Sanjay Jain, CFO, FDC talks about the reasons behind company's revenue surge, growth plans and the challenges they are facing. Excerpts:

    ET Now: What has really been the reasons for this kind of a revenue surge and which are the products that have contributed to this?
    Sanjay Jain:
    The reason basically for the increase in the margins is because of the increase in some of the products during the year. So that has helped us in improving the margins. The products are in the wide range across all the therapies.

    ET Now: And in terms of your revenue surge, if you can tell us which products have contributed?
    Sanjay Jain:
    We have in our portfolio basically a wide range of antibiotics and anti-diarrheal products which has really helped us in improving the margins.

    ET Now: Let us also talk a little bit about the ANDA filing, what is the future pipeline for the same?
    Sanjay Jain:
    So, as far as the US is concerned, we have about 10-12 ANDA already in our list and in about next month or so we may file one more ANDA.

    ET Now: Your debt also seems to have come off, so tell us what is the current debt situation, what are your plans to offset debt?
    Sanjay Jain:
    We do not have any debt in our books. Except for one marginal loan in the form of sales tax deferral loan, we do not have any debt in our books.

    ET Now: Any FDA inspections, any of the plans in the near term that is planned?
    Sanjay Jain:
    Recently only in our Baddi plant we have finished the USFDA inspection and we are waiting for their approval.

    ET Now: Let us just talk about your margin picture, this time around it has been very healthy, what kind of margins are you pencilling in going forward
    Sanjay Jain:
    So, going forward there are lots of challenges as far as the margin are concerned because of the triple impact in the pharma industry across for all the companies. So, first is the WPI impact which was negative by 2.71% for the entire year.

    Second impact will be on account of the various price notifications and third on account of the fixed dose combination ban. So, that will be a challenge going forward for the financial year 2016-2017.
    The Economic Times

    Stories you might be interested in